مؤشر حيوي جديد لتطور سرطان البنكرياس وانتشارهsnoR

Joanna K, Pawel G,Small Nucleolar RNAs Tell a Different Tale. Trends Genet. 2019; 35(2): 104-117. https://dx.doi.org/10.1016/j.tig.2018.11.005 .

De Zoysa MD, Yu YT. Posttranscriptional RNA pseudouridylation. Enzymes. 2017; 1(41): 151-67. https://dx.doi.org/10.1016/bs.enz.2017.02.001

Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-willi syndrome. Genet Med. 2012; 14(1): 10-26. https://doi.org/10.1038/gim.0b013e31822bead0

Mourksi NEH, Morin C, Fenouil T, Diaz JJ, Marcel V. snoRNAs Offer Novel Insight and Promising Perspectives for Lung Cancer Understanding and Management . Cells. 2020; 9(3): 541. https://doi.org/10.3390/cells9030541.

Dsouza VL, Adiga D, Sriharikrishnaa S, Suresh PS, Chatterjee A, Kabekkodu SP. Small nucleolar RNA and its potential role in breast cancer–A comprehensive review. Biochim Biophys Acta Rev Cancer. 2021; 1875(1): 188501. https://doi.org/10.1016/j.bbcan.2020.188501 .

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, et al. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol. 2017; 19(7): 844–855. https://doi.org/10.1038/ncb3563 .

Yi C, Wan X, Zhang Y, Fu F, Zhao C, Qin R, et al. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis. Int J Biochem Cell Biol. 2018; 1(102): 138-50. https://doi.org/10.1016/j.biocel.2018.07.009 .

Kitagawa T, Taniuchi K, Tsuboi M, Sakaguchi M, Kohsaki T, Okabayashi T, et al. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer. Mol Oncol. 2019; 13(2): 212-227. https://doi.org/10.1002/1878-0261.12398

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. https://doi.org/10.3322/caac.21590 .

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin A V., et al. Pancreatic cancer. Nat Rev Dis Primers. 2016; 2(1): 1–22. https://doi.org/10.1038/nrdp.2016.22 .

Pittman ME, Rao R, Hruban RH. Classification, morphology, molecular pathogenesis, and outcome of premalignant lesions of the pancreas. Arch Pathol Lab Med. 2017; 141(12): 1606-14. https://doi.org/10.5858/arpa.2016-0426-RA .

Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis M V. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Onco. 2020; 12(2): 173–181. https://doi.org/10.4251/wjgo.v12.i2.173 .

Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. In: Progress in Molecular Biology and Translational Science. Prog Mol Biol Transl Sci. 2016; 144: 241–75. https://doi.org/10.1016/bs.pmbts.2016.09.008 .

Mas L, Lupinacci RM, Cros J, Bachet JB, Coulet F, Svrcek M. Intraductal papillary mucinous carcinoma versus conventional pancreatic ductal adenocarcinoma: A comprehensive review of clinical-pathological features, outcomes, and molecular insights. Int J Mol Sci. 2021; 22(13): 6756-. https://doi.org/10.3390/ijms22136756

Puckett Y, Sharma B, Kasi A. Intraductal Papillary Mucinous Cancer Of The Pancreas. StatPearls. 2022. https://www.ncbi.nlm.nih.gov/books/NBK507779/

McCann KL, Kavari SL, Burkholder AB, Phillips BT, Hall TMT. H/ACA snoRNA levels are regulated during stem cell differentiation. Nucleic Acids Res. 2020; 48(15): 8686-8703. https://doi.org/10.1093/nar/gkaa612 .

Steinbusch MMF, Fang Y, Milner PI, Clegg PD, Young DA, Welting TJM, et al. Serum snoRNAs as biomarkers for joint ageing and post traumatic osteoarthritis. Sci Rep. 2017; 7: 43558. https://doi.org/10.1038/srep43558 .

Roake CM, Artandi SE. Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol. 2020 Jul; 21(7): 384-97. https://doi.org/10.1038/s41580-020-0234-z

Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2011 Jan; 140(1): 310-21. https://doi.org/10.1053/j.gastro.2010.10.009 .

Vila-Navarro E, Duran-Sanchon S, Vila-Casadesús M, Moreira L, Ginès À, Cuatrecasas M, et al. Novel circulating miRNA signatures for early detection of pancreatic neoplasia. Clin Transl Gastroentero. 2019; 10(4): e00029. https://doi.org/10.14309/ctg.0000000000000029

Zhang X, Shi S, Zhang B, Ni Q, Yu X, Xu J. Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. Am J Cancer Res. 2018; 8(3): 332-353

Farivar S, Amirinejad R, Naghavi gargari B, Hassani SB, Shirvani farsani Z. In Silico Analysis of Regulatory Elements of the Vitamin D Receptor. Baghdad Sci J. 2020. 17(2): 463-470. https://doi.org/10.21123/bsj.2020.17.2.0463

Muraki T, Jang KT, Reid MD, Pehlivanoglu B, Memis B, Basturk O, et al. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. Mod Pathol. 2022; 35(1): 96-105. https://doi.org/10.1038/s41379-021-00902-x .

Bruner HC, Derksen PWB. Loss of E-cadherin-dependent cell–cell adhesion and the development and progression of cancer. Cold Spring Harb Perspect Biol. 2018; 10(3): a029330. https://doi.org/10.1101/cshperspect.a029330 .

Goodman SR. Goodman's Medical Cell Biology. 4th edition. Memphis: Academic Press. 2021. Chap 3. Cytoskeleton; p.57-100. https://doi.org/10.1016/B978-0-12-817927-7.00003-X

Jaiswal P, Yadav YK, Sinha SS, Singh MK. Expression of cytokeratin 8 in oral squamous cell cancer. Indian J Pathol Oncol. 2018; 5(1): 55-60. https://doi.org/10.18231/2394-6792.2018.0011

Wang S, Huang S, Sun YL. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. Biomed Res Int. 2017; 2017: 2646148-2646158. https://doi.org/10.1155/2017/2646148 .

Park HS, Han HJ, Lee S, Kim GM, Park S, Choi YA, et al. Detection of circulating tumor cells in breast cancer patients using cytokeratin-19 real-time RT-PCR. Yonsei Med J. 2017; 58(1): 19-26. https://doi.org/10.3349/ymj.2017.58.1.19 .

Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M, et al. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2015; 25(448): 161-9. https://doi.org/10.1016/j.cca.2015.06.027 .

Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration. F1000Res. 2018; 7: 1796-10. https://doi.org/10.12688/f1000research.15967.1

Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells. 2019; 8(5): 497-518. https://doi.org/10.3390/cells8050497 .

Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M, Rosel D. Vimentin intermediate filaments as potential target for cancer treatment. Cancers. 2020; 12(1): 184. https://doi.org/10.3390/cancers12010184 .

Beardo P, Truan Cacho D, Izquierdo L, Alcover-Garcia JB, Alcaraz A, Extramiana J, et al. Cancer-specific survival stratification derived from tumor expression of tissue inhibitor of metalloproteinase-2 in non-metastatic renal cell carcinoma. Pathol Oncol Res. 2019; 25(1): 289-99. https://doi.org/10.1007/s12253-017-0339-7 .

Ismael MK. The Prognostic Value of some Epithelial-Mesenchymal Transition Markers and Metastasis-Related Markers in Human Transitional Cell Carcinoma of the Bladder. Baghdad Sci J. 2018;15(3):244-252. https://doi.org/10.21123/bsj.2018.15.3.0244

Pietrzak J, Szmajda-Krygier D, Wosiak A, Świechowski R, Michalska K, Mirowski M, et al. Changes in the expression of membrane type-matrix metalloproteinases genes (MMP14, MMP15, MMP16, MMP24) during treatment and their potential impact on the survival of patients with non-small cell lung cancer (NSCLC). Biomed Pharmacother. 2022; 146: 112559-112567. https://doi.org/10.1016/j.biopha.2021.112559

Fang Z, Liang W, Luo L. HSP27 promotes epithelial-mesenchymal transition through activation of the β-catenin/MMP3 pathway in pancreatic ductal adenocarcinoma cells. Transl Cancer Res. 2019; 8(4): 1268-1278. https://doi.org/10.21037/tcr.2019.07.13

Slapak EJ, Duitman J, Tekin C, Bijlsma MF, Spek CA. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?. Biology (Basel). 2020; 9(4): 80-101 https://doi.org/10.3390/biology9040080 .

Saw P .E, Song EW. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell. 2019; 10(11): 787–807. https://doi.org/10.1007/s13238-019-0639-7

Pedrosa RM, Mustafa DA, Soffietti R, Kros JM. Breast cancer brain metastasis: molecular mechanisms and directions for treatment. Neuro Oncol. 2018; 20(11): 1439-49. https://doi.org/10.1093/neuonc/noy044

Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, et al. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017; 32(2): 185-203. https://doi.org/10.1016/j.ccell.2017.07.007

Steins A, Mackelenbergh MG van, Zalm AP van der, Klaassen R, Serrels B, Goris SG, et al. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. EMBO Rep. 2020; 21(5): e48780. https://doi.org/10.15252/embr.201948780 .